Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study
- Authors
- Kim, Jeongseok; Yoon, Hyuk; Kim, Nayoung; Lee, Kang-Moon; Jung, Sung-Ae; Choi, Chang Hwan; Kim, Eun Soo; Jung, Yunho; Eun, Chang Soo; Kim, Tae Oh; Kang, Sang-Bum; Kim, You Sun; Seo, Geom-Seog; Lee, Chang Kyun; Im, Jong Pil; Park, Soo Jung; Park, Dong Il; Ye, Byong Duk
- Issue Date
- Dec-2021
- Publisher
- OXFORD UNIV PRESS INC
- Keywords
- vedolizumab; Crohn disease; ulcerative colitis; Korea
- Citation
- INFLAMMATORY BOWEL DISEASES, v.27, no.12, pp 1931 - 1941
- Pages
- 11
- Journal Title
- INFLAMMATORY BOWEL DISEASES
- Volume
- 27
- Number
- 12
- Start Page
- 1931
- End Page
- 1941
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/52797
- DOI
- 10.1093/ibd/izaa361
- ISSN
- 1078-0998
1536-4844
- Abstract
- Background: We investigated the real-life effectiveness and safety of vedolizumab (VDZ) induction therapy among Korean patients with Crohn disease (CD) or ulcerative colitis (UC) for whom anti-tumor necrosis factor therapy previously failed. Methods: Adult patients who started VDZ induction therapy at 16 centers were prospectively enrolled in the Korean VDZ nationwide registry. The coprimary outcomes were clinical remission, defined as a Crohn's Disease Activity Index score <150 points and a partial Mayo score <= 2 points with a combined rectal bleeding and stool frequency subscore <= 1 point at week 14 and endoscopic remission defined as a Mayo endoscopic subscore <= 1 point. We also analyzed predictors of clinical remission. Results: Between August 2017 and November 2019, a total of 158 patients (80 with CD and 78 with UC) received VDZ induction therapy. Clinical remission rates among patients with CD and patients with UC were 44.1% and 44.0%, respectively. Among patients with UC, the endoscopic remission rate was 32.4%. Clinical response and remission rates showed increasing trends during induction therapy. Multivariable analysis revealed that clinical response at week 6 was the only predictor of clinical remission at week 14 for both patients with CD and patients with UC. Among patients who experienced 1 or more adverse events (n = 71; 44.9%), disease exacerbation (n = 28; 17.7%) was the most common adverse event. Conclusions: Among Korean patients with CD or UC for whom anti-tumor necrosis factor therapy failed, VDZ induction therapy was effective and safe. The early clinical response was associated with clinical remission after VDZ induction therapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/52797)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.